MEI Historical Balance Sheet
MEIP Stock | USD 2.70 0.10 3.57% |
Trend analysis of MEI Pharma balance sheet accounts such as Total Stockholder Equity of 32.7 M provides information on MEI Pharma's total assets, liabilities, and equity, which is the actual value of MEI Pharma to its prevalent stockholders. By breaking down trends over time using MEI Pharma balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining MEI Pharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether MEI Pharma is a good buy for the upcoming year.
MEI Pharma Inventory |
|
MEI |
About MEI Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of MEI Pharma at a specified time, usually calculated after every quarter, six months, or one year. MEI Pharma Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of MEI Pharma and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which MEI currently owns. An asset can also be divided into two categories, current and non-current.
MEI Pharma Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of MEI Pharma assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in MEI Pharma books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on MEI Pharma balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of MEI Pharma are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Most accounts from MEI Pharma's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into MEI Pharma current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MEI Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in MEI Stock, please use our How to Invest in MEI Pharma guide.At this time, MEI Pharma's Property Plant And Equipment Gross is relatively stable compared to the past year. As of 12/15/2024, Property Plant Equipment is likely to grow to about 16 M, while Total Stockholder Equity is likely to drop slightly above 32.7 M.
2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 9.9M | 11.0M | 5.2M | 3.9M | Total Assets | 177.8M | 120.8M | 41.4M | 62.7M |
MEI Pharma balance sheet Correlations
Click cells to compare fundamentals
MEI Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
MEI Pharma balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 209.7M | 174.1M | 177.8M | 120.8M | 41.4M | 62.7M | |
Other Current Liab | 6.1M | 7.5M | 9.9M | 11.0M | 5.2M | 3.9M | |
Total Current Liabilities | 23.3M | 30.3M | 24.4M | 20.3M | 8.4M | 8.3M | |
Total Stockholder Equity | 78.2M | 41.4M | 52.4M | 24.6M | 33.0M | 32.7M | |
Net Debt | (12.3M) | (245K) | (6.1M) | (4.2M) | (3.7M) | (3.9M) | |
Accounts Payable | 2.4M | 6.4M | 7.9M | 6.1M | 3.2M | 2.2M | |
Cash | 12.3M | 8.5M | 15.7M | 16.9M | 3.7M | 3.5M | |
Cash And Short Term Investments | 182.6M | 153.4M | 153.3M | 100.7M | 38.3M | 57.3M | |
Common Stock Shares Outstanding | 4.6M | 5.7M | 6.3M | 6.7M | 6.7M | 7.0M | |
Liabilities And Stockholders Equity | 209.7M | 174.1M | 177.8M | 120.8M | 41.4M | 62.7M | |
Other Current Assets | 5.6M | 3.8M | 7.7M | 11.3M | 2.4M | 1.9M | |
Other Stockholder Equity | 355.5M | 369.2M | 426.6M | 430.6M | 421.2M | 442.3M | |
Total Liab | 131.5M | 132.7M | 125.4M | 96.2M | 8.4M | 7.9M | |
Total Current Assets | 208.6M | 164.8M | 167.1M | 107.5M | 40.8M | 60.9M | |
Retained Earnings | (277.2M) | (327.8M) | (374.2M) | (406.0M) | (388.2M) | (368.8M) | |
Short Term Investments | 170.3M | 144.9M | 137.5M | 83.8M | 34.6M | 32.9M | |
Non Current Liabilities Total | 46.3M | 20.4M | 108.2M | 102.4M | 101.0M | 75.8M | |
Property Plant And Equipment Net | 1.1M | 9.3M | 10.7M | 13.3M | 606K | 575.7K | |
Non Current Assets Total | 1.1M | 9.3M | 10.7M | 13.3M | 606K | 575.7K | |
Property Plant And Equipment Gross | 1.1M | 9.3M | 11.4M | 14.3M | 2.4M | 2.9M | |
Property Plant Equipment | 1.1M | 9.3M | 10.7M | 13.3M | 15.3M | 16.0M | |
Net Tangible Assets | 78.2M | 41.4M | 52.4M | 24.6M | 28.3M | 48.6M | |
Retained Earnings Total Equity | (214.4M) | (231.2M) | (277.2M) | (327.8M) | (295.0M) | (309.8M) | |
Capital Surpluse | 264.9M | 279.1M | 355.5M | 369.2M | 424.5M | 255.0M | |
Non Currrent Assets Other | (1.1M) | (9.3M) | (10.7M) | (13.3M) | (12.0M) | (11.4M) | |
Current Deferred Revenue | 14.8M | 14.6M | 4.8M | 317K | 364.6K | 346.3K | |
Net Invested Capital | 78.2M | 41.4M | 52.4M | 24.6M | 33.0M | 37.9M | |
Net Working Capital | 185.3M | 134.5M | 142.7M | 87.2M | 32.4M | 30.8M | |
Other Liab | 108.2M | 95.1M | 92.2M | 64.5M | 74.2M | 78.2M | |
Net Receivables | 20.4M | 7.6M | 10.0M | 85K | 76.5K | 72.7K |
Pair Trading with MEI Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if MEI Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in MEI Pharma will appreciate offsetting losses from the drop in the long position's value.Moving against MEI Stock
0.55 | FLGC | Flora Growth Corp | PairCorr |
0.37 | DYAI | Dyadic International | PairCorr |
0.35 | DNA | Ginkgo Bioworks Holdings | PairCorr |
0.32 | ESPR | Esperion Therapeutics | PairCorr |
0.32 | IMAB | I Mab | PairCorr |
The ability to find closely correlated positions to MEI Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace MEI Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back MEI Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling MEI Pharma to buy it.
The correlation of MEI Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as MEI Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if MEI Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for MEI Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for MEI Stock Analysis
When running MEI Pharma's price analysis, check to measure MEI Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MEI Pharma is operating at the current time. Most of MEI Pharma's value examination focuses on studying past and present price action to predict the probability of MEI Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MEI Pharma's price. Additionally, you may evaluate how the addition of MEI Pharma to your portfolios can decrease your overall portfolio volatility.